Development For Agenebio News Today : Breaking News, Live Updates & Top Stories | Vimarsana

AgeneBio Announces Completion of Patient Enrollment in Phase 2B Clinical Trial to Evaluate AGB101 to Treat Amnestic Mild Cognitive Impairment Due to Alzheimer s Disease
- Topline results expected in November 2022
News provided by
Share this article
Share this article
BALTIMORE, April 21, 2021 /PRNewswire/  AgeneBio announced today that it has completed enrollment in a Phase 2B clinical trial evaluating the efficacy of AGB101, a once-a-day investigational medication to treat amnestic Mild Cognitive Impairment due to Alzheimer s Disease (MCI due to AD). The clinical trial, known as HOPE4MCI (NCT03486938), is a 78-week study, randomized, double-blind, placebo controlled study that has enrolled 164 patients across 23 sites in the United States and Canada. ....

United States , Sharon Rosenzweig Lipson , Richard Mohs , Johns Hopkins University , National Institutes Of Health , Clinical Development For Agenebio , John Hopkins University , Agenebio Inc , Johns Hopkins Center , Alzheimer Drug Discovery Foundation , Development For Agenebio , Mild Cognitive Impairment , Clinical Dementia Ratings Scale , Mini Mental State Exam , Functional Activities Questionnaire , Cerveau Technologies , Imaging Science , Vice President , Clinical Development , Principal Investigator , Drug Discovery , National Institute On Aging , National Institutes , Memory Function , Amnestic Mild Cognitive Impairment , ஒன்றுபட்டது மாநிலங்களில் ,